A study monitoring clinical course of Idiopathic Pulmonary Fibrosis in a real‑world setting over 5 years: PROOF registry.

Trial Profile

A study monitoring clinical course of Idiopathic Pulmonary Fibrosis in a real‑world setting over 5 years: PROOF registry.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Acetylcysteine (Primary) ; Corticosteroids (Primary) ; Nintedanib (Primary) ; Pirfenidone (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Therapeutic Use
  • Acronyms PROOF
  • Sponsors Genentech; Roche
  • Most Recent Events

    • 12 Jul 2017 New trial record
    • 24 May 2017 Results (n=277; data cut off 13 septmber 2016) presented at the 113th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top